Jan. 8, 2024 8:00 am ET
Merck & Co.has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.
Merck on Monday said it will pay $23 a share in cash for Harpoon, more than double Friday’s closing price of $10.55 for the South San Francisco, Calif., company.
Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
